Health systems

Cancer care continues to innovate and evolve at astounding speeds, presenting complex challenges to health systems that want to provide meaningful care for their patients.
A health care provider seated at a conference table with colleagues having a discussion.
Exact Sciences understands the business health systems run, and the challenges they face along the cancer care continuum. From risk to remission, our expertise in cancer detection, therapy guidance, and monitoring can help enhance your health system's approach to cancer care.

Loading component...

Together, we can:

Optimize and automate workflows that support clinicians and staff

Address population health, equity, and quality goals

Provide personalized, end-to-end support for patients along their journey

Real-world experience

See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.

Cancer screening solutions that work on your terms to optimize cancer detection

Our screening portfolio is designed to get every eligible patient screened with the right test. We're focused on providing innovative solutions at speed and scale, in one comprehensive portfolio, backed by end-to-end support. Our cancer screening portfolio includes:

Colorectal cancer (CRC) screening

  • For average-risk patients aged 45+ — the Cologuard Plus® test is an FDA-approved stool DNA test that offers early-stage detection of colorectal cancer (CRC).1
  • For patients who remain unscreened — the SimpleScreen™ CRC test is an FDA approved screening option for average-risk patients 45+. CRC blood tests are recommended by the American Cancer Society (ACS) for those who will not complete a preferred screening test.2,3†

Multi-cancer early detection

  • The Cancerguard® test — an innovative multi-cancer early detection (MCED) test that complements standard-of-care screening and can help detect multiple cancers with a simple blood draw.4
Lab technician putting samples into a piece of equipment.
An Exact Sciences lab technician opening an OncoExTra test kit box.

Precision oncology: Testing for every stage of care

Exact Sciences’ Precision Oncology portfolio doesn't stop with a test's science. It also reflects the realities of the clinical setting and what providers can face when ordering tests and delivering results to patients.

Pairing comprehensive, world-class genomic tests like the Oncotype DX® test with a connected digital infrastructure

  • Helps to efficiently create a complete picture of each patient's unique cancer
  • Enables providers and their patients to focus on what matters most—the best way forward

We’re equipped to integrate solutions into your workflows, streamlining your genomic cancer testing and helping you match your patients with emerging personalized treatments.

ExactNexus™ technology platform: Streamlined and secure care

Our ExactNexus technology platform helps create a unified clinical experience within the Exact Sciences ecosystem to deliver our tests and seamlessly connect health systems, providers, payers, and patients.
ExactNexus by Exact Sciences.

Connect with us

Let’s discuss how we can support your health system’s cancer screening goals.

We're aligned with your priorities.

Industry partnerships with organizations like the ones listed below connect Exact Sciences directly to the evolving priorities of health system leaders, ensuring the solutions we develop are aligned with real-world clinical, operational, and strategic needs.
America College of Healthcare Executives for leaders who care.
Visit our corporate partner page at ACHE.org for our latest on-demand webinars, videos, case studies, and articles.
AMGA.
Visit our corporate partner page at AMGA.org for our latest webinars and other resources.

Important Information about the Cologuard products

The Cologuard test and Cologuard Plus test are indicated to screen adults, 45 years or older, who are at average risk for CRC. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. Not a replacement for colonoscopy in high-risk individuals. False positive and negative results may occur. Rx only. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk- information.

Important Information about the SimpleScreen CRC test

SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

Precaution: Based on data from clinical studies, SimpleScreen CRC has limited detection (57%) of Stage I colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy. Rx only. IVD. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk-information.

Developed and manufactured by Freenome, LLC. Distributed by Abbott.

Important Information about the Cancerguard test

The Cancerguard test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. False positive and negative results may occur. The Cancerguard test is a Laboratory Developed Test, it has not been cleared or approved by the US Food and Drug Administration. Rx only. See more at cancerguard.com/indications-for-use.